your stock | future of orchid pharma, rel comm, inox leisure & more | cnbc tv18
Published 6 years ago • 4.3K plays • Length 20:45
Download video MP4
Download video MP3
Similar videos
-
1:36
sp tulsian on the future of inox leisure stock | cnbc tv18
-
5:00
orchid pharma partners with cipla for antibiotic cefepime-enmetazobactam, launch likely in august
-
1:09
orchid pharma under pressure. revenue & margin decline on qoq basis | cnbc tv18
-
1:17
orchid pharma surges in trade after investec initiates a 'buy' rating with target of ₹800 |cnbc tv18
-
2:01
orchid pharma antibiotic 'exblifeb' gets approval from european medicines agency | cnbc tv18
-
6:10
chinese consumers are spending more on experiences not stuff, says shehzad qazi on pinduoduo decline
-
55:26
orchid pharma: business update on amalgamation
-
5:22
dow closes at record high: why the market's biggest bull sees a volatility comeback
-
1:04
orchid pharma launches`400 cr qip, indicative issue price at ₹403.93/sh as per sources | cnbc tv18
-
7:17
cdmo business has been seeing margin of 14-15%: akums drugs & pharma | cnbc tv18
-
8:36
dcgi has asked for phase 4 clinical trials for enmetazobactam drug: orchid pharma | cnbc tv18
-
5:37
stick to guidance of 20% topline growth & 26-27% ebitda margin in fy25: vinati organics | cnbc tv18
-
1:21
earnings cheer: orchid pharma locked in upper circuit ma | midcap radar | business news | cnbc-tv18
-
1:11
emcure pharma gains after jefferies initiates coverage with buy rating & target price of ₹1,600
-
6:44
co growing at 15-20% per annum & hope to continue growth momentum for next 3-4 yrs: orchid pharma
-
10:04
investorai secures ₹80 crore in funding fueling company's growth & expand products | startup central
-
7:39
positive on domestic cyclicals – power, real estate, capex & mfg: alchemy capital mgmt | cnbc tv18
-
5:35
according to estimates, sales of exblifeb could hit $2-3bn in the next 10 yrs: orchid pharma
-
2:40
orchid pharma gets us fda nod for novel drug enmetazobactum used to treat urinary tract infection
-
6:41
key stocks in focus: medi assist, gpt infraprojects, ceigall, zydus lifesciences, hcltech, coforge
-
0:53
emcure pharma ipo listing: shares debut at nearly 32% premium over ipo price | n18s | cnbc tv18
-
6:27
the company has turned profitable in q3 with revenue rising 123% yoy: inox wind | cnbc tv18
Clip.africa.com - Privacy-policy